Trial Profile
A phase 1 study of ABT-869 in patients withrefractory or relapsed acute myelogenous leukaemia or myelodysplastic syndrome
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Aug 2006
Price :
$35
*
At a glance
- Drugs Linifanib (Primary) ; Cytarabine
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 07 Aug 2006 New trial record.